Jul 22, 2010 by Brian Orelli, PhDThey've Come, Now Build ItNot meeting demand is no way to run a business.
Jul 22, 2010 by Brian Orelli, PhDOne Surgery Dominated, A Hundred More to GoIntuitive Surgical isn't slowing down.
Jul 21, 2010 by Brian Orelli, PhDBiogen Looks Good Now, but What About Tomorrow?The pipeline for one drugmaker is crumbling.
Jul 21, 2010 by Brian Orelli, PhDBoston Scientific BouncesDespite last night's after-hours rise, it still has gravity working against it.
Jul 21, 2010 by Brian Orelli, PhD15% Revenue Growth Is Good for Pfizer, but Not GileadGilead needs to reaccelerate growth.
Jul 20, 2010 by Brian Orelli, PhDIs J&J a Bad News Buy?A turnaround in the making; it's just a question of when.
Jul 20, 2010 by Brian Orelli, PhDWhy Are Pfizer's Shares Down on an Up Day?More clinical trials get stopped.
Jul 19, 2010 by Brian Orelli, PhDAbbott Labs Loves Merck More Than GileadIts HIV trial seems to suggest so.
Jul 16, 2010 by Brian Orelli, PhDA Positive Sign for Pharma Earnings SeasonBut maybe it doesn't bode well for everyone; Novartis is special.
Jul 15, 2010 by Brian Orelli, PhDThe Blockbuster Drug Survives Another Body BlowAvandia is still standing.
Jul 15, 2010 by Brian Orelli, PhDInjecting Generic Growth Is Good for InvestorsMylan fills in a niche.
Jul 15, 2010 by Brian Orelli, PhDInsider Buying at MonsantoMonsanto's CEO and CFO bought shares. Should you?
Jul 13, 2010 by Brian Orelli, PhDA Triple Delight: 3 Stocks All Up More Than 10%What's good for the obese goose is good for the gander.
Jul 12, 2010 by Brian Orelli, PhDJohnson & Johnson MENDs a HoleAnother neurovascular device maker gets snatched up.
Jul 9, 2010 by Brian Orelli, PhDChanging Pay-For-Delay Will Hurt EveryoneCongress and the FTC could be poised to make a big mistake.
Jul 9, 2010 by Brian Orelli, PhDHey, Johnson & Johnson: Eight Is EnoughThese recalls are getting a little ridiculous.
Jul 9, 2010 by Brian Orelli, PhD2 Days, 1 Blockbuster, Fate UnknownAvandia's fate is in the hands of an FDA advisory panel.
Jul 8, 2010 by Brian Orelli, PhDSurprise Us in a Good Way, MerckKeeping up productivity during plant closures won't be easy.
Jul 7, 2010 by Brian Orelli, PhDThat's Gotta Hurt: Recommending the CompetitionSupply constraints continue to plague Genzyme.
